AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 million plus other costs by the end of 2021.
Oxford Biomedica said in a statement that under the deal it would mass-produce the potential vaccine, AZD1222, for the novel coronavirus for a period of 18 months, which may be further extended by another 18 months into 2022 and 2023.
Read more:
Coronavirus: No one will be forced to get COVID-19 vaccine, says Brazil's Bolsonaro
World’s first Phase III COVID-19 vaccine trials in UAE reaches 31,000 volunteers
China’s Sinovac coronavirus vaccine approved for emergency use: Source
